Treatment performance measures affect clinical outcomes in patients with acute systolic heart failure: Report from the Korean Heart Failure Registry

Circulation Journal

Volumn 76, Issue 5, 2012, Pages 1151-1158

  Youn, Young Jin ^a   Yoo, Byung Su ^a,b   Lee, Jun Won ^a   Kim, Jang Young ^a   Han, Seong Woo ^c   Jeon, Eun Seok ^d   Cho, Myeong Chan ^e   Kim, Jae Joong ^f   Kang, Seok Min ^g   Chae, Shung Chull ^h   Oh, Byung Hee ⁱ   Choi, Dong Ju ^j   Lee, Myung Mook ^k   Ryu, Kyu Hyung ^l  

^a Yonsei University Wonju   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Korea University College of Medicine   (South Korea)

^d Samsung Medical Center   (South Korea)

^e Chungbuk National University Hospital   (South Korea)

^f Asan Medical Center   (South Korea)

^g Yonsei University College of Medicine   (South Korea)

^h Kyungpook National University Hospital   (South Korea)

ⁱ Seoul National University   (South Korea)

^j Seoul National University Bundang Hospital   (South Korea)

^k Dongguk University Ilsan Hospital   (South Korea)

^l Hallym University Medical Center   (South Korea)

more..

Author keywords

Left ventricular systolic dysfunction; Mortality; Performance measures

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; COMORBIDITY; DISEASE REGISTRY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HOSPITAL READMISSION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENERGIC BETA-ANTAGONISTS; ADVANCE DIRECTIVE ADHERENCE; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; REGISTRIES; REPUBLIC OF KOREA; SURVIVAL RATE; TASK PERFORMANCE AND ANALYSIS;

EID: 84860290579     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1093     Document Type: Article

References (41)

1. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
3. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007; 297: 61-70.
4. Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: The MAHLER survey. Eur Heart J 2005; 26: 1653-1659.
5. Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, et al. National patterns of use and effectiveness of angiotensinconverting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110: 724-731.
6. Bonow RO, Bennett S, Casey DE Jr, Ganiats TG, Hlatky MA, Konstam MA, et al. ACC/AHA clinical performance measures for adults with chronic heart failure: A report of the American College of Cardiol ogy/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J Am Coll Cardiol 2005; 46: 1144-1178.
7. Joint Commission on Accreditation of Healthcare Organizations. Specifications manual for national hospital quality measures, 2006. http:// www.jointcommission.org/PerformanceMeasurement/Performance Measurement/Historical+NHQM+manuals.htm (accessed December 4, 2006).
8. Fonarow GC. Improving quality of care and outcomes for heart failure: Role of registries. Circ J 2011; 75: 1783-1790.
9. Shroff GR, Taylor AL, Colvin-Adams M. Race-related differences in heart failure therapies: Simply black and white or shades of grey? Curr Cardiol Rep 2007; 9: 178-181.
10. Palaniappan LP, Araneta MR, Assimes TL, Barrett-Connor EL, Carnethon MR, Criqui MH, et al. Call to action: Cardiovascular disease in Asian Americans: A science advisory from the American Heart Association. Circulation 2010; 122: 1242-1252.
11. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J 2010; 160: 1156-1162.
12. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84.
13. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006; 27: 2725-2736.
14. Lenzen MJ, Scholteop Reimer WJ, Boersma E, Vantrimpont PJ, Follath F, Swedberg K, et al. Differences between patients with a preserved and a depressed left ventricular function: A report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214-1220.
15. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-777.
16. Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, et al. Characteristics, outcomes, and predictors of long-term mortality in patients hospitalized for acute heart failure: A report from the Korean Heart Failure (KorHF) Registry. Korean Circ J 2011; 41: 363-371.
17. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-1900.
18. Maeda JL. Evidence-based heart failure performance measures and clinical outcomes: A systematic review. J Card Fail 2010; 16: 411-418.
19. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: Analysis of the ADHERE Registry. Arch Intern Med 2005; 165: 1469-1477.
20. Kfoury AG, French TK, Horne BD, Rasmusson KD, Lappe DL, Rimmasch HL, et al. Incremental survival benefit with adherence to standardized heart failure core measures: A performance evaluation study of 2958 patients. J Card Fail 2008; 14: 95-102.
21. Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005; 111: 179-185.
22. VanSuch M, Naessens JM, Stroebel RJ, Huddleston JM, Williams AR. Effect of discharge instructions on readmission of hospitalised patients with heart failure: Do all of the Joint Commission on Accreditation of Healthcare Organizations heart failure core measures reflect better care? Qual Saf Health Care 2006; 15: 414-417.
23. Lappe JM, Muhlestein JB, Lappe DL, Badger RS, Bair TL, Brockman R, et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 2004; 141: 446-453.
24. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
25. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
26. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
27. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-781.
28. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
29. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al; MERIT-HF Study Group. Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-1302.
30. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
31. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390.
32. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
33. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-380.
34. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
35. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
36. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184-192.
37. Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, Hamaguchi S, Yokota T, Goto D, et al. Beta-blocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circ J 2010; 74: 1364-1371.
38. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-330.
39. Hori M, Okamoto H, Matsuzaki M, Izumi T, Yamazaki T, Yoshikawa T, et al. Randomized trial to optimize the dose and efficacy of betablocker in systolic heart failure: Japanese Chronic Heart Failure (JCHF) Study. In: Proceedings of the 82th American Heart Association meeting 2009 (Orlando, FL, USA).
40. Johnson JA. Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics. Circulation 2008; 118: 1383-1393.
41. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.